InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 3 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

1
Player Avatar portefeuille (99.78) Submitted: 12/16/2011 12:13:30 AM : Outperform Start Price: $25.44 ITMN Score: -67.22

There are currently 14500 ITMN shares in my "fund" with break-even of around 8.70 USD. http://caps.fool.com/Blogs/fund-trades/678775.

Report this Post Reply

Featured Broker Partners


Advertisement